Case Report
An Unusual Course of Metastatic Gastroesophageal Cancer
Table 1
Summary of the literature reviewed on neoadjuvant chemoradiotherapy in GEJ cancer.
| | | Median F/U (years) | Population (% of patients) | Randomization (patients) | Overall survival | Progression-free survival | | Median (years) | 3–5 years (%) | Median (years) | 3–5 years (%) |
|
Van Hagen et al. (2012) [4]
CROSS trial | 3.8 | Resectable esophageal (73%) or GEJ (24%) CA | Carboplatin + paclitaxel/41.4 Gy + surgery (178) | 4.1 | (5 yr) | — | — | | Surgery alone (188) | 2.0 | (5 yr) | — | — |
|
Tepper et al. (2008) [5]
CALGB 9781 trial | 6.0 |
Stages I–III of CA of esophagus or GEJ | Cisplatin + 5-FU/50.4 Gy + surgery (30) | 4.5 | 39% (5 yr) | 3.5 | 28% (5 yr) | | Surgery alone (26) | 1.8 | 16% (5 yr) | 1.0 | 15% (5 yr) |
|
Stahl et al. (2009) [18]
POET trial | 3.8 |
Locally advanced adenocarcinoma of GEJ | Cisplatin + 5-FU + leucovorin/30 Gy + surgery (60) | 2.8 | 47.4% (3 yr) | — | 76.5% (3 yr) | | Cisplatin + 5-FU + leucovorin + surgery (59) | 1.8 | 27.7% (3 yr) | — | 59.0% (3 yr) |
| |
Burmeister et al. (2005) [19] | 5.4 | Esophageal CA including lower third/gastric cardia (79%) | Cisplatin + 5-FU/35 Gy + surgery (128) | 1.9 | 11.7% (5 yr) | 1.3 | 10.2% (5 yr) | | Surgery alone (128) | 1.6 | 7.8% (5 yr) | 1.0 | 7.0% (5 yr) |
| |
Walsh et al. (1996) [20] | 0.8 | Esophageal CA including lower third/cardia (85%) | Cisplatin + 5-FU/40 Gy + surgery (58) | 1.3 | 32% (3 yr) | — | — | | Surgery alone (55) | 0.9 | 6% (3 yr) | — | — |
| |
Urba et al. (2001) [21] | 8.2 |
Stages I–III of CA of esophagus or GEJ | Cisplatin + 5-FU + vinblastine/45 Gy + surgery (50) | 1.4 | 30% (3 yr) | — | 28% (3 yr) | | Surgery alone (50) | 1.5 | 16% (3 yr) | — | 16% (3 yr) |
|
|
(i) Statistically significant value.
(ii) F/U: follow-up, CA: cancer, 5-FU: 5-fluorouracil, and yr: years.
(iii) —: not reported.
|
